Navigation Links
AMP comments at FDA meeting on next-generation sequencing
Date:6/23/2011

June 23, 2011 (Bethesda, MD): Today, on behalf of the Association for Molecular Pathology (AMP), Dr. Elaine Lyon gave public comments at the US Food and Drug Administration's (FDA) meeting on "Ultra High Throughput Sequencing for Clinical Diagnostic Applications Approaches to Assess Analytical Validity." As they begin developing their program to evaluate sequencing based diagnostics, AMP advised FDA officials on many important considerations for evaluating analytical validity.

The analytical validation requirements for NGS will vary based on the clinical application at issue, such as a mutation panel for a Mendelian disease versus transcriptome analysis. Also, performance of, and coverage needs for, a given platform are likely to differ depending on the nucleic acid analyzed, the characteristics of the DNA regions and the type of variations interrogated, the relative allele proportions of particular variants, and whether quantitative or qualitative results are desired. For these reasons, Dr. Lyon noted "this necessitates flexibility and individualization in the development of validation protocols, guidelines, and controls on an application-by-application basis."

While the analytical validity of a NGS instrument may be intrinsically very high, its data conversion and analysis software may have design flaws or performance limitations. As such, AMP told the FDA that for optimal FDA review of the test system, the analytical validity of the instrument and the performance of the bioinformatics software should be evaluated both independently and as a complete system.

AMP also pointed out the role of molecular pathology professionals in determining the most appropriate platform and technologies for answering the clinical question at issue and advised the FDA to be careful not to limit the practice of medicine. "Optimal patient care requires the ability of molecular pathology professionals to use their professional opinion of the most suita
'/>"/>

Contact: Mary Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Page: 1 2

Related biology news :

1. AMP comments at FDA meeting on array-based tests
2. AMP submits comments on SACGHS report
3. Director of Berman Institute comments on FDA Approval of first human embryonic stem cell trial
4. Registration opens for first Middle East and Africa osteoporosis meeting
5. MARC travel award announced for GSA C. elegans meeting
6. Scientists at the Ecological Society of Americas 2011 Annual Meeting to discuss global stewardship
7. Sound research at Acoustical Society meeting
8. MARC Travel awards announced for the Endocrine Societys 93rd Annual Meeting and Expo
9. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
10. NYU Langone experts present advances at American Association of Neurological Surgeons Meeting
11. NIDCD research at AChemS Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Ore. For several years, the pharmaceutical industry has ... receptor in the brain, the NMDA receptor. This receptor ... brain and is involved in learning and memory. NMDA ... psychiatric conditions such as Alzheimer,s disease, Parkinson,s disease, schizophrenia ...
... J. Carver Charitable Trust has awarded a $2 million ... University of Illinois at Urbana-Champaign. Under the leadership of ... Christopher Rao, the grant will be disbursed over two ... new research theme devoted to the new scientific subdiscipline ...
... Journal of Animal Science suggests producers may ... grains with solubles (DDGS). Some producers believe that feeding ... DDGS. Firmer fat means longer-lasting pork. But researchers ... fats in DDGS diets makes no difference in fat ...
Cached Biology News:OHSU scientists advance understanding of brain receptor; may help fight neurological disorders 2Roy J. Carver Charitable Trust funds new research focus at Institute for Genomic Biology 2Saturated fats do not yield better bacon 2
(Date:2/26/2015)... 2015 S&P Capital IQ (MHFI) announced today ... on MabVax Therapeutics Holdings Inc . ... biotechnology company focused on the development of vaccine and ... treatment of cancer. MabVax has discovered a pipeline of ... responses generated by patients who have been immunized against ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading personal ... Black as Privacy Officer and Corporate Counsel. Black ... privacy laws as well as health care regulations. As ... will be responsible for reviewing, updating and enhancing the ... U.S. and abroad. She joined the company January 5, ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
(Date:2/26/2015)... Protiviti ( www.protiviti.com ), a global consulting ... Governance Portal , designed to increase the efficiency with ... across multiple business units and projects. The Governance Portal ... align their controls with the COSO ( Committee of ... response to client feedback, Protiviti has also included a ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... 23 Summary: At Genmab A/S,Annual General Meeting held ... was approved, discharge was given to the Board of ... forward. Two members of the,Board of Directors were re-elected ... proposals from the Board of,Directors to change the Articles ...
... Calif., April 23 STAAR Surgical,Company (Nasdaq: ... of,minimally invasive ophthalmic products, today announced very strong,participation ... on the Company,s,Visian ICL(TM) (Implantable Collamer Lens). The ... "How My Website Compels Patients to Call,Me," is ...
... April 23 Two,leading companies in the ... a new commercial alliance. IOTA Pharmaceuticals Ltd, ... in Uppsala, Sweden, will join forces,to deploy ... The IOTA-Beactica platform couples comprehensive, site-directed ...
Cached Biology Technology:Passing of Genmab A/S' Annual General Meeting 2Passing of Genmab A/S' Annual General Meeting 3Passing of Genmab A/S' Annual General Meeting 4More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 2More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 3New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden) 2
...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
... with carbonyl diimidazole chemistry that covalently binds ... array contains the same binding chemistry as ... updated hydrophobic barrier coating. These arrays are ... spots spatially compatible with one column of ...
Biology Products: